Myelodysplastic Syndrome Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia, Adult; Myelodysplastic Syndrome(MDS); Allogeneic Hematopoietic Stem Cell Transplantation Interventions: Drug: Fludarabine and Busulfan; Drug: Fludarabine and Melphalan Sponsor: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Leukemia; Relapsed; Myeloid; Acute Intervention: Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor: Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia, Adult; Myelodysplastic Syndrome(MDS); Allogeneic Hematopoietic Stem Cell Transplantation Interventions: Drug: Fludarabine and Busulfan; Drug: Fludarabine and Melphalan Sponsor: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Leukemia; Relapsed; Myeloid; Acute Intervention: Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor: Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia, Adult; Myelodysplastic Syndrome(MDS); Allogeneic Hematopoietic Stem Cell Transplantation Interventions: Drug: Fludarabine and Busulfan; Drug: Fludarabine and Melphalan Sponsor: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Leukemia; Relapsed; Myeloid; Acute Intervention: Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor: Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia, Adult; Myelodysplastic Syndrome(MDS); Allogeneic Hematopoietic Stem Cell Transplantation Interventions: Drug: Fludarabine and Busulfan; Drug: Fludarabine and Melphalan Sponsor: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Leukemia; Relapsed; Myeloid; Acute Intervention: Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor: Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia, Adult; Myelodysplastic Syndrome(MDS); Allogeneic Hematopoietic Stem Cell Transplantation Interventions: Drug: Fludarabine and Busulfan; Drug: Fludarabine and Melphalan Sponsor: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Leukemia; Relapsed; Myeloid; Acute Intervention: Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor: Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia, Adult; Myelodysplastic Syndrome(MDS); Allogeneic Hematopoietic Stem Cell Transplantation Interventions: Drug: Fludarabine and Busulfan; Drug: Fludarabine and Melphalan Sponsor: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Leukemia; Relapsed; Myeloid; Acute Intervention: Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor: Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia, Adult; Myelodysplastic Syndrome(MDS); Allogeneic Hematopoietic Stem Cell Transplantation Interventions: Drug: Fludarabine and Busulfan; Drug: Fludarabine and Melphalan Sponsor: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials